• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

CPhl Research Shows Growth for Biologics and Generics


The 16th edition of CPhI Japan-organized by UBM EMEA and UBM Asia-returned to Tokyo last week, April 19-21. The event released new research for the Japanese pharma market. More than 90 domestic and international companies that attended the event were surveyed to provide a complete picture of Japan’s best growth opportunities. Domestic companies predict a 17% increase for 2017.

An analysis displayed that 56% of companies think that biologics and biosimilars showed the fasted growth for the upcoming year. It states that companies believe the most popular biopharmaceutical product classes in development are anticancer (72%) and enhanced immune class rugs (48%).

Japan is the world’s third largest pharmaceutical industry, with a thriving domestic market. Only 18% of business for Japanese pharma is within international markets, yet the research shows that over two thirds are looking to target international markets over the next year. Half of companies target the US and 27% are looking to China and Korea.

The complete report highlighting Japanese pharmaceutical market statistics and analysis will be available later in the year, on the CPhl Pharma Insights website here.